PHIBRO ANIMAL HEALTH CORP
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 16.2
- Dividend yield
- 1.22%
Earnings
Next report expected Nov 4, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2026 Ended Jun 30, 2026 | Aug 26, 2026 | During market hours | $396.70M | $0.53 | $0.85 |
| Q3 FY2026 Ended Mar 31, 2026 | May 6, 2026 | During market hours | $383.50M | $0.59 | $0.76 |
| Q2 FY2026 Ended Dec 31, 2025 | Feb 4, 2026 | During market hours | $373.90M | $0.67 | $0.87 |
| Q1 FY2026 Ended Sep 30, 2025 | Nov 5, 2025 | During market hours | $363.90M | $0.65 | $0.73 |
| Q4 FY2025 Ended Jun 30, 2025 | Aug 27, 2025 | During market hours | $378.70M | $0.42 | $0.57 |
| Q3 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | $347.80M | $0.51 | $0.63 |
| Q2 FY2025 Ended Dec 31, 2024 | Feb 5, 2025 | During market hours | $309.30M | $0.08 | $0.54 |
| Q1 FY2025 Ended Sep 30, 2024 | Nov 6, 2024 | During market hours | $260.40M | $0.17 | $0.35 |
| Q4 FY2024 Ended Jun 30, 2024 | Aug 28, 2024 | During market hours | $273.20M | $0.02 | $0.41 |
| Q3 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | $263.20M | $0.21 | $0.31 |
| Q2 FY2024 Ended Dec 31, 2023 | Feb 7, 2024 | During market hours | $249.90M | $0.03 | $0.33 |
Company guidance
Outlook given with results on Aug 26, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| Adjusted EBITDAnon-GAAP | year ending June 30, 2027 | $258.00M to $268.00M | New |
| Adjusted diluted EPSnon-GAAP | year ending June 30, 2027 | $3.41 to $3.59 | New |
| Diluted EPSGAAP | year ending June 30, 2027 | $2.98 to $3.22 | New |
| Adjusted net incomenon-GAAP | year ending June 30, 2027 | $140.00M to $147.00M | New |
| Net incomeGAAP | year ending June 30, 2027 | $122.00M to $132.00M | New |
| Adjusted net income growthnon-GAAP | year ending June 30, 2027 | 9% growth | Raised |
| Adjusted EBITDA growthnon-GAAP | year ending June 30, 2027 | 3% growth | New |
| Diluted EPS growthGAAP | year ending June 30, 2027 | 27% growth | Maintained |
| Adjusted diluted EPS growthnon-GAAP | year ending June 30, 2027 | 9% growth | Maintained |
| Adjusted effective income tax ratenon-GAAP | year ending June 30, 2027 | 20% | New |
| Net income growthGAAP | year ending June 30, 2027 | 27% growth | New |
| Net sales | year ending June 30, 2027 | $1.55B to $1.60B | New |
| Net sales growth | year ending June 30, 2027 | 4% growth | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Phibro Animal Health filed with the SEC
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Announces Regulatory Framework
Regulation FD disclosure · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Announces Leadership Transition
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance
Results of operations · Shareholder vote results · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance
Results of operations · Shareholder vote results · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Health Corporation Completes Acquisition of Zoetis’ Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products
Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Zoetis to Sell Medicated Feed Additive Portfolio
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Announces Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reiterates
Regulation FD disclosure · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Announces Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Third Quarter and Year-to-Date Results
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Second Quarter Results
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Announces the
Executive or director change · Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports First Quarter Results, Revised Guidance
Results of operations · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Declares Quarterly Dividend
Other events · EX-99.1 to Form 8-K
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
Results of operations · EX-99.1 to Form 8-K